Requis devises new OTC and Rx drugs as well as nutraceutical products. A key part of the strategy is patent protection
Requis Pharmaceuticals Inc. is a new product-focused Biotech company that is developing a series of de-risked pharmaceutical and nutraceutical products based in part on the new science of tryptophan, the precursor of the central nervous system (CNS) neurotransmitter serotonin. Serotonin is known as a universal "feel good" synaptic neurotransmitter.
Requis' initial focus is on Sleep Disordered Breathing (SDB) in particular; lead product Requisom is being developed as a remedy for Obstructive Sleep Apnea (OSA). Sleep apnea is a highly prevalent condition affecting at least 4% of men and 2% of women; many sufferers go undiagnosed in an estimated market of over 20 M Americans. Untreated OSA is associated with increased cerebrovascular, cardiovascular (CV) and cancer morbidity and sudden death.
The company invents, develops and then seeks out-licensing partners for commercially attractive pharmaceutical and consumer health products for US and worldwide markets. Requis Pharma has filed a series of US/PCT patent applications; four of them are now published; it proactively seeks IP protection on all its products. Requis is the French word for "required" and Latin for sleep is "somnum" - so Requisom = "required for sleep". Requis is now executing a focused plan to drive its compelling new products into the marketplace.
The founders of Requis Pharma have published a range of top level Pharma industry publications
Requis Pharma's approach to new drugs for sleep disorders has been featured in MedCity News, published in Philadelphia
Capturing new products based on the innovative science of L-tryptophan - an amino acid essential for human health
CEO Lars Knutsen outlines the company's achievements to date, along with exciting plans for growing the business, to prospective investors at the Mid-Atlantic Diamond Venture Forum at Philadelphia Country Club
“I have been involved with Requis since its inception as an adviser and guide. CEO Lars Knutsen and his team have delivered on all objectives in building an exciting new venture"
Requis Pharma has provided a series of Investor Presentations in 2014, and a recent one is included here